Clinical Trial

A Study of AP505 Injection in Patients With Advanced Malignant Solid Tumors

Name: A Study of AP505 Injection in Patients With Advanced Malignant Solid Tumors — clinical trial record (NCT06723964)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary anti-tumor activity of AP505 injection in patients with advanced solid tumors. The study will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) for AP505.

Trial Details

NCT Number	NCT06723964
Lead Sponsor	AP Biosciences Inc.
Conditions	Advanced Solid Tumors
Enrollment	35 participants
Start Date	2023-03-30
Primary Completion	2024-10-31 (estimated)
Study Completion	2025-11-30 (estimated)
Updated on ClinicalTrials.gov	2024-12-09